Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715239 | 0.94 | ALDH1A1 (0.64) | ALDH1A1RECQLLTA4HBACE1HDAC1 | |
| SCHEMBL30230040 | 0.92 | ALDH1A1 (0.59) | ALDH1A1RECQLLTA4HBACE1HDAC1 | |
| SCHEMBL22266169 | 0.92 | ALDH1A1 (0.59) | ALDH1A1RECQLLTA4HBACE1HDAC1 | |
| SCHEMBL25123531 | 0.91 | ALDH1A1 (0.58) | ALDH1A1RECQLLTA4HBACE1HDAC1 | |
| SCHEMBL9453041 | 0.89 | HDAC1 (0.61) | ALDH1A1RECQLLTA4HBACE1HDAC1 | |
| SCHEMBL10330870 | 0.87 | ALDH1A1 (0.53) | ALDH1A1RECQLLTA4HBACE1HDAC1 | |
| SCHEMBL7817624 | 0.86 | GSTP1 (0.60) | ALDH1A1RECQLLTA4HFFAR1FFAR4 | |
| SCHEMBL19226911 | 0.86 | ALDH1A1 (0.65) | ALDH1A1RECQLLTA4HBACE1HDAC1 | |
| SCHEMBL7642691 | 0.85 | ALDH1A1 (0.55) | ALDH1A1RECQLLTA4HBACE1HDAC1 | |
| SCHEMBL4323479 | 0.85 | FFAR4 (0.57) | ALDH1A1RECQLLTA4HBACE1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150594-A1 | POLYCARBONATE RESIN COMPOSITION AND MOLDED ARTICLE COMPRISING SAME | 帝人株式会社 | 2024-07-18 | — | — | WO | disclosed |
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| US-7071180-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2006-07-04 | — | — | US | disclosed |
| EP-1099692-B1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1178973-B1 | PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-6737425-B1 | SUCH AS 1-((4-CYANO-5-METHYL-4-PHENYL)HEXYL)-4-(2-(4-FLUORO -PHENOXY)ETHYL)PIPERAZINE; NERVE SELECTIVE CALCIUM ANTAGONISTS | EISAI CO., LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| US-6476258-B1 | Process for producing aryloxyacetic acids | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
| EP-1067108-A2 | Process for producing aryloxyacetic acids | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | ALDH1A1 763/4885RECQL 2320/4885LTA4H 1451/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | ALDH1A1 724/4885RECQL 2293/4885LTA4H 1404/4885 |
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | ALDH1A1 383/4885RECQL 2015/4885LTA4H 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.